TL;DR — Key Takeaways
- In a friendly-PC/MSO structure, malpractice coverage and its eventual tail sit on the clinical side of the line: they protect professional liability, which belongs to the professional corporation and its clinicians.
- An MSO paying the physicians’ or PC’s tail is not automatically unlawful, but it raises corporate-practice questions, because who bears clinical liability costs is one signal of who really controls, and profits from, the practice.
- SB 351, effective January 1, 2026, codified California’s corporate practice prohibitions against private equity and hedge fund arrangements, voids offending contract terms, and arrived alongside visible Attorney General enforcement against MSO structures in 2026.
- The safer drafting pattern keeps clinical insurance, tail included, as a practice expense borne on the PC side, with the MSO’s role limited to administration, and the management fee set at fair market value for the services actually provided.
- Investor-backed transactions involving MSOs now also face California’s pre-closing notice regime, with implementing regulations still in motion as of drafting.
The Direct Answer
In an MSO-managed practice, the tail question is really a control question wearing an insurance costume. Malpractice liability is clinical; the corporate practice of medicine doctrine exists to keep clinical matters, and the economics that drive them, with licensed professionals. So when a management services agreement makes the MSO the payer of the physicians’ tail, it plants a flag on the wrong side of the line, one more fact suggesting the unlicensed entity bears the practice’s professional risks and rewards. The allocation can often be structured defensibly. But in 2026, with new legislation in force and the Attorney General actively unwinding MSO arrangements it considers over-controlling, “we’ve always done it this way” is not a drafting strategy.
Bay Legal, PC advises California practices, MSOs, and investors on management structures, MSA drafting, and the compliance questions that ride along. Call (650) 668-8000 in Northern California or (213) 668-8000 in Southern California.
The Structure, in One Paragraph
The friendly-PC/MSO model separates a medical practice into two entities: a professional corporation, owned by licensed clinicians, that employs providers and delivers care; and a management services organization, which non-licensees and investors may own, that provides business services, space, equipment, staffing, billing, administration, under a management services agreement for a fee. California’s corporate practice of medicine doctrine polices the boundary: the PC must genuinely control clinical matters, and the MSO’s role must genuinely be management. We cover the doctrine and the structure in depth in our medical business law content; this post takes one narrow question, who pays for malpractice coverage and its tail, and follows it through the doctrine.
Why Insurance Sits on the Clinical Side
Most MSA cost allocations are unremarkable: rent, software, and billing staff are business expenses, and the MSO providing them is what management means. Malpractice insurance is different in kind. It prices, absorbs, and manages the risk of clinical care itself. That is why the allocation carries doctrinal weight in ways the copier lease never will:
Bearing clinical risk looks like owning the practice. Regulators evaluating whether a PC is genuinely independent look past the org chart at the economics. When the MSO funds the defense of clinical judgment, insures the clinical enterprise, and pays the tail when clinicians leave, an enforcer can argue the MSO holds the real risks and rewards of practicing medicine, the substance the doctrine cares about.
Control follows the checkbook. The entity paying for coverage tends to acquire say over it: carrier selection, limits, whether to settle a claim, which departing physician’s tail gets bought. Several of those, settlement consent above all, sit close to the clinical core. An MSA that hands the MSO contractual authority over the practice’s insurance decisions has moved actual control, not just cost.
Fee-splitting adds a second lens. California’s fee-splitting prohibition polices arrangements where compensation flows in ways that look like paying for patients or dividing professional revenue. Insurance costs absorbed by an MSO whose fee floats with practice revenue can feed an argument that the arrangement is really a profit split. Percentage-based management fees are not per se unlawful in California, but they must be defensible as fair market value for real services, and every clinical cost the MSO absorbs makes the FMV story harder to tell.
None of this makes MSO-paid tail categorically illegal; the doctrine is enforced on whole arrangements, not single line items. It makes it a fact that counts against you, in a year when the facts are being counted.
SB 351 and the 2026 Enforcement Environment
SB 351, effective January 1, 2026, codified the corporate-practice prohibitions as applied to private equity groups and hedge funds involved with California physician and dental practices. In general terms, as of drafting: it bars investor-side entities from controlling core clinical matters, identifies categories of professional decisions that must remain with licensees, voids offending contract provisions, and gives the Attorney General express enforcement authority. It arrived into an enforcement environment that was already moving: 2026 has seen the AG extract public settlements from MSO arrangements, including negotiated judgments identifying specific MSA features, among them sweeping MSO authority over clinician hiring, firing, and compensation, as impermissible control, alongside pending appellate litigation over how far the doctrine reaches into MSO contract rights. The direction of travel is unmistakable even where the precise lines are not.
For tail allocation, the lesson is not that SB 351 mentions insurance; it is that MSAs are being read, closely, by an enforcer scoring control. Insurance provisions are part of that read. If you are drafting or refreshing an MSA in this environment, Bay Legal, PC can help you get the allocation right before someone else grades it. Reach us at baylegal.com/contact, or call (650) 668-8000 or (213) 668-8000.
The Drafting Patterns
How MSAs commonly handle clinical insurance and tail, from cleanest to riskiest:
PC bears the cost; MSO administers. Malpractice premiums and any tail are practice expenses of the PC, paid from practice revenue before the management fee or expressly carved out as PC obligations. The MSO may procure quotes, process paperwork, and calendar deadlines as an administrative service, while the PC holds decision rights: carrier, limits, consent to settle. This is the pattern that keeps the clinical-risk economics where the doctrine wants them.
Employer-style obligations inside the PC. Who pays a departing physician’s tail is then a question between the PC and its physician, governed by the employment agreement, and everything in our employment-side posts applies, including the new limits on repayment clauses for post-2025 agreements. The MSO stays out of that lane.
MSO advances, PC reimburses. Sometimes cash-flow reality has the MSO fronting costs. Documented as an advance against practice expenses, trued up transparently, it is defensible; drifting into the MSO simply eating clinical costs, it starts telling the wrong story.
MSO pays, full stop. The pattern to avoid, particularly where the MSA also gives the MSO authority over insurance decisions or ties its fee to practice revenue. Each element is a control fact; stacked, they are a narrative.
MSA termination deserves its own section. When a PC-MSO relationship ends, the practice’s claims-made policies face the same tail-or-continuity question as any departure, and the wind-down allocation, who buys the entity tail, what happens to coverage the MSO administered, belongs in the MSA before anyone is angry. Silence here produces exactly the dispute-plus-deadline collision our termination post warns about.
Investor Deals: The AB 1415 Overlay
Transactions in this space now carry a procedural layer. AB 1415, also effective January 1, 2026, extended California’s healthcare transaction-notice regime to “noticing entities,” private equity groups, hedge funds, MSOs, and certain newly formed entities, requiring advance notice to the state’s Office of Health Care Affordability before material change transactions, generally on a 90-day pre-closing clock. As of drafting, OHCA’s implementing regulations remain proposed rather than final: draft emergency regulations published in May 2026 would, among other things, set a low ownership threshold for investor filings, refine which MSOs are covered, and reach certain real-estate structures, with final emergency regulations targeted to take effect in the second half of 2026. Parties are expected to comply with the statute in the meantime. For deal planning, budget the notice period into the timeline, expect diligence on the MSA’s control features, insurance provisions included, and confirm the regulations’ current status before signing, because the details are moving.
Structure questions in this area are unforgiving of improvisation and generous to preparation. Bay Legal, PC works with California practices and their counterparties on MSAs, restructurings, and transactions built to hold up. Call (650) 668-8000 (Northern California) or (213) 668-8000 (Southern California), or contact us at baylegal.com/contact.
Frequently Asked Questions
Can an MSO legally pay for a physician’s tail coverage in California?
It is not categorically prohibited, but it is a control-and-economics fact that counts in a corporate-practice analysis, and it rarely stands alone. The safer pattern treats clinical insurance and tail as PC-side practice expenses, with the MSO limited to administration. Arrangements should be evaluated as a whole by counsel.
Does SB 351 say anything about malpractice insurance or tail?
SB 351 addresses control of professional matters by private equity and hedge fund-connected entities rather than insurance line items specifically. Its practical effect is that MSAs are being scrutinized for where control and clinical economics sit, and insurance provisions are part of that picture.
Who buys the tail when a PC and MSO part ways?
Whatever the MSA and related agreements provide, which is exactly why the wind-down allocation belongs in the documents at signing. The practice’s claims-made coverage needs the same tail-or-continuity answer as any transition, on the carrier’s election timeline.
Do percentage-based management fees make tail allocation riskier?
They raise the stakes. A revenue-based fee must be defensible as fair market value for the management services provided, and clinical costs absorbed by the MSO make that showing harder while feeding fee-splitting and control arguments. Flat, FMV-benchmarked fees with clean cost allocations tell a simpler story.
